Amgen: Tepezza (teprotumumab) Receives Approval In Japan For The Treatment Of Active Thyroid Eye Disease
Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high ...
Medindia5h
TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease (TED) ...
dvm36014h
Biopharmaceutical seeks to raise $15M to develop cancer therapy for pets
CureLab Veterinary Inc, a biopharmaceutical company that develops cancer treatments for pets, announced a Regulation D ...
These Are the Most Common Colon Cancer Symptoms in Young People
Researchers recently looked at the most common initial red flags of colorectal cancer in people younger than 50 and published ...
Northern Arizona Jewish News16h
Gut-friendly recipes for the High Holidays
Crohn’s disease and ulcerative colitis, which are the most common types of inflammatory bowel disease (IBD), are more common ...
Why the key to preventing cancer under 50 lies in your gut
Cancer cases in the under-50s are rising, and experts believe it may be linked to their gut health. Here’s how to fix it ...